ReviewPathologica2020
Intraductal carcinoma of the prostate.
Review in Pathologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading.Prostate cancer and prostatic diseases · 2023Pooled it
- Identification of factors associated with intraductal carcinoma of the prostate.Diagnostic pathology · 2026Article
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- Article
- Article
- Review
- Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.Journal of cancer research and clinical oncology · 2024Article
- Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.American journal of clinical and experimental urology · 2024Article
- Cribriform pattern in prostate tissues: Predictor for intraductal carcinoma of the prostate based on biopsy and radical prostatectomy pathology.BJUI compass · 2023Article
- Construction and validation of a clinical predictive nomogram for intraductal carcinoma of the prostate based on Chinese multicenter clinical data.Frontiers in oncology · 2022Article
- Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion.Frontiers in oncology · 2022Article
- Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information.Insights into imaging · 2021Review
- Circular RNA UBAP2 promotes the proliferation of prostate cancer cells via the miR-1244/MAP3K2 axis.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraductal carcinoma of the prostate (IDC-P) is a diagnostic entity characterized by architecturally or cytologically malignant-appearing prostatic glandular epithelium confined to prostatic ducts. Despite its apparent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.